Journal Menu

Issues

Drug Invention Today
ISSN NO: 0975-7619
Drug Invention Today (DIT) was first published in 2009 by JPR Solutions. It is a journal, which publishes reviews, research papers and short communications . From 2019  Journal will be monthly twice ( vol 11& 12 with 2 Issues per month)
• Novel Drug Delivery Systems • Nanotechnology & Nanomedicine • Biotechnology related pharmaceutical technology • Polymeric bio-conjugates • Biological macromolecules • Biomaterials • Drug Information • Drug discovery/development • Screening of drugs from natural & synthetic origins • Novel therapeutic strategies • Combinatorial chemistry and parallel synthesis • Clinical trials • Case Reports
 Impact FactorTM ( India ) = 0.895 as on date (09.11.2018)
Indexed in
NCBI NLM Catalogue,
SCOPUS, EMBASE (Elsevier),
SCIMAGO, CAS,
ROAD, CABI, Google Scholar,
Open J-Gate, Biblioteca,
Science Central,
Index Scholar, Indian Citation Index,
 AYUSH Research Portal, 
Indexed Copernicus, EBSCO, PSOAR,
Ulrichs Directory of Periodicals, etc.

      Recent Manuscripts published

      Journal: Drug Invention Today

      Title: Risk factors and protective factors of mental health during coronavirus disease-19 outbreak and lockdown in adult Indian population – A cross-sectional study
      Section: Research Article
      Category: Pharmacology
      Country: India
      View Article

      Background: The novel coronavirus (CoV) has derailed the entire world and various steps have been taken by the health authorities to tackle this pandemic. Nationwide lockdown has been imposed to control the spread of CoVs disease (COVID-19) outbreak in India, which could have psychological impact on the population. Aim: Our study aims to study the effect of the COVID-19 outbreak and subsequent lockdown on mental health status of adult Indian population along with identifying the high-risk groups. Methodology: An online survey was conducted during the 3rd phase of lockdown gathering details about sociodemographic variables, practice of precautionary measures, awareness and concerns regarding COVID-19, and mental health status of the participants through Depression Anxiety Stress Scale-21 questionnaire from 873 adults. Results: The prevalence of depression, anxiety, and stress was 18.56%, 25.66%, and 21.99%, respectively, including higher number of participants with mild depression (15.1%) and stress (14.5%) and moderate anxiety (16.3%). Female gender, age <25 years, unemployment, self-business, employed in private sector, lack of formal education, larger household size, and parenthood (>2 kids) were associated with increased likelihood of negative mental health. Confidence in physician’s ability to diagnose COVID-19 infection, decreased self-perceived likelihood of contracting COVID-19, lesser frequency of checking for information on COVID-19, and satisfaction of information received were protective against negative mental health. Conclusion: This landmark study identified the protective and risk factors of mental health during COVID-19 pandemic, to help authorities and mental health workers to strategize and deliver interventional methods to maintain psychosocial well- being of the population.

      Journal: Drug Invention Today

      Title: Oral health status, dental awareness, and dental services utilization barriers among transgender population in Chennai
      Section: Research Article
      Category: Pharmacology
      Country: India
      View Article

      Background: Transgender (TG) community is one of the most underprivileged communities in India. Their accessibility to dental facilities is very scarce. Thus, they are more vulnerable to severe dental problems such as dental decay and tooth loss. Aim: The present cross-sectional study aimed to evaluate (1) the status of oral health, (2) the knowledge on oral health, and (3) the dental utilization barriers among the TG residing in Chennai, Tamil Nadu, India. Materials and Methods: Dental decay, filled teeth, missing teeth, etc., were assessed on clinical examination among 72 TG and a self-evaluated questionnaire was also distributed. Data obtained were analyzed using SPSS IBM software. Results: The overall oral health was perceived to be very poor, with more than half suffering from untreated dental caries. The mean values and standard deviations, respectively, of decayed, missing, filled components were 1.89 and 1.773, 0.83 and 2.664, and 0.15 and 0.522, respectively. Over 30% of the population believed that a painful tooth was the reason one must visit the dentist. Over 60% of the participants had not visited the dentist at all. The reason major reason being, 15.7% felt the treatment being too expensive, 22.9% were scared of the dentist. Over 77.1% agreed that there were no dental awareness camps held in the past, while 54.3% still felt neglected to avail oral health care. The majority of 91.4% strongly request the government to frame dental health schemes. Conclusion: There has to be an immediate intervention of the dental institutions and the government bodies to raise the oral health quality among the TG community.

      Journal: Drug Invention Today

      Title: Requirements of biopharmaceutics and clinical research for abbreviated new drug application submission – USA
      Section: Review Article
      Category: Pharmaceutics
      Country: India
      View Article

      The objective of the study is to understand the biopharmaceutic requirements for the submission of abbreviated new drug application (ANDA) for the United States Food and Drug Administration (USFDA), how to conduct the bioavailability/ bioequivalence (BE) studies, and how to submit those information to the agency, electronic common technical document structure for the dossier compilation, the significance of the BE to prove the rate and extent of the drug product is same as the branded drug product, this article also emphasizes on the FDA requirements for conducting the clinical studies. Generic drugs are the drugs, which are similar to the brand/reference listed product, not withstand the difference in strength, quality, dosage form, performance, route of administration, intended use, and characteristics. To get an approval from the USFDA for the marketing of generic drug, we need to file an ANDA. The BE can be achieved only if the rate and extent of absorption do not show a major difference from the reference listed drug (RLD), to demonstrate that the generic drug product is bioequivalent to the RLD all of the clinical study report data needed to be submitted in the module 5. Nowadays, more number of generic drugs are coming into the market; hence, the drug product will be available at the cheaper rate, but at the same time, the safety of the drug product is also very important; hence, the biopharmaceutics study is essential for the ANDA submission.